Xenon Q3 net loss $37.2M; launches XEN1101 Phase 3 epilepsy program

Xenon Pharmaceuticals Inc.

2022-Q3 EPS reported -$1.49 revenue$9,434,000

Revenue $0.1M vs $8.1M YoY; no Neurocrine milestone in Q3 2022.
Cash $752.2M as of Sep 30, 2022; expected runway into 2026.
XEN1101 Phase 3 trials X-TOLE2, X-TOLE3 (FOS) and X-ACKT (PGTCS) initiated.
X-NOVA MDD Phase 2 topline data expected Q3 2023.
R&D expenses $29.4M, up 56% YoY, driven by XEN1101 program.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xenon Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the six and nine months ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.